Ger­man ra­dio­phar­ma forms an­oth­er Chi­na joint ven­ture; Urovan­t's Gemte­sa pass­es blood pres­sure study

Ger­man biotech ITM is form­ing a joint ven­ture with Chi­nese ra­dio­phar­ma play­er Cheng­du Gao­tong Iso­tope.

This ven­ture fol­lows a strate­gic part­ner­ship be­tween ITM and the Chi­na Iso­tope and Ra­di­a­tion Cor­po­ra­tion (CIRC) which was ini­tial­ly formed in 2010 and fur­ther ex­tend­ed in No­vem­ber 2019.

The new­ly formed com­pa­ny is sched­uled to start op­er­a­tions by the end of the year and will be lo­cat­ed in Cheng­du, Chi­na. This will be ITM’s sec­ond lo­ca­tion in Chi­na af­ter open­ing its first sub­sidiary in Shang­hai ear­li­er this year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER